Benzinga

Benzinga

Benzinga

jeudi, août 20

Amneal Pharmaceuticals Inc

AMRXNASDAQ
Trade with Public
Trade with Public
$17.95
-0.16-0.88%
Dern. MÀJ: Aug 20, 12:19 PM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Amneal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amneal Pharmaceuticals (AMRX).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingOverweight# Analysts6Avg. Consensus PT$14Upside to Avg. PT-22.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026UBSAshwani VermaPT RaiseBuy$23→$25
Jul 15, 2026UBSAshwani VermaPT RaiseBuy$19→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
Benzinga Newsdesk

PRO
UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $17

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $15 to $17.
Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Amneal Pharmaceuticals with Overweight Rating, Announces Price Target of $15

Barclays analyst Glen Santangelo initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight rating and announces Price Target of $15.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved